Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of the Pharmacokinetics, Safety, Tolerability and Efficacy of Entecavir (ETV) in Pediatric Subjects With Chronic Hepatitis B Virus (HBV) Infection Who Are HBeAg-Positive

Trial Profile

Evaluation of the Pharmacokinetics, Safety, Tolerability and Efficacy of Entecavir (ETV) in Pediatric Subjects With Chronic Hepatitis B Virus (HBV) Infection Who Are HBeAg-Positive

Completed
Phase of Trial: Phase I/II

Latest Information Update: 04 May 2018

At a glance

  • Drugs Entecavir (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 07 Sep 2017 Status changed from active, no longer recruiting to completed.
    • 18 Jun 2016 Results assessing population pharmacokinetic from five trials published in the Clinical Pharmacokinetics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top